Published: Vol 3, Iss 4, Feb 20, 2013 DOI: 10.21769/BioProtoc.329 Views: 13819
Protocol Collections
Comprehensive collections of detailed, peer-reviewed protocols focusing on specific topics
Related protocols
PBMC-Humanized Mouse Model for Multiple Sclerosis: Studying Immune Changes and CNS Involvement
Anastasia Dagkonaki [...] Lesley Probert
May 20, 2025 1728 Views
Isolation and Imaging of Microvessels From Brain Tissue
Josephine K. Buff [...] Sophia M. Shi
Aug 5, 2025 979 Views
Novel Experimental Approach to Investigate Immune Control of Vascular Function: Co-culture of Murine Aortas With T Lymphocytes or Macrophages
Taylor C. Kress [...] Eric J. Belin de Chantemèle
Sep 5, 2025 172 Views
Abstract
The NSG-CTL mouse model is a humanized mouse model that allows the generation of peripheral human immune responses, particularly CD8+ Cytotoxic T lymphocyte (CTL) responses, and serves as an effective model for studying gene-based therapies. Natural antigen-specific T cell responses in humanized mice are relatively weak and this model was developed to boost antigen specific responses, in this case to HIV, to more closely assess these responses in vivo. We have engineered human T cells that develop in these mice to express a molecularly cloned T cell receptor (TCR) specific to HIV. Cloned TCRs to any antigen can theoretically be used to study specific responses in vivo, as long as the tissue that is manipulated is of the same human leukocyte antigen (HLA) type. The modification of hematopoietic stem cells with antigen specific TCRs allows the development of mature, functional T cells in the periphery of these mice that are specific to that antigen following normal developmental processes. This model has recently been published (Kitchen et al., 2012) and this was a major modification of the Humanized Mouse BLT model published by Melkus et al. (2006). We use Non-obese diabetic (NOD)-Severe Combined Immunodeficient (SCID), common Gamma chain knockout (γc-/-)—or NSG—mice, and implant fetal thymus pieces along with genetically modified CD34+ hematopoietic stem cells (HSCs), isolated from fetal liver, under the kidney capsule to develop into a functional thymic implant. At the same time, we deplete the mouse’s bone marrow by total body irradiation and inject more modified HSCs intravenously for hematopoietic engraftment in the mouse bone marrow. This protocol outlines the procedures to process the fetal tissue, genetically transduce the HSCs using lentiviral vectors expressing a molecularly cloned T cell receptor, and perform the subcapsular kidney implant surgery.
Processing Fetal Thymus and Isolating CD34+ Cells from Fetal Liver
Materials and Reagents
Equipment
Procedure
Transducing CD34+ Cells
Materials and Reagents
Equipment
Procedure
Tissue Transplants to Construct NSG-CTL Mice
Materials and Reagents
Equipment
Procedure
Variation
Acknowledgments
This work was funded by grants from the NIH (number R01AI078806 (S.G.K), the California HIV/AIDS Research Program (CHRP) (number 163893) (S.G.K.), the UC Multicampus Research Program and Initiatives from the California Center for Antiviral Drug Discovery (number MRPI-143226), and from funding by the UCLA Center for AIDS Research (CFAR) (number P30 AI28697).
References
Article Information
Copyright
© 2013 The Authors; exclusive licensee Bio-protocol LLC.
How to cite
Readers should cite both the Bio-protocol article and the original research article where this protocol was used:
Category
Immunology > Immune cell function > Lymphocyte
Immunology > Animal model > Mouse
Cell Biology > Tissue analysis > Tissue isolation
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Share
Bluesky
X
Copy link